Clinical trials: Diabetes Type I
Hypoglycemia
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of…
- Trial name
- NCT02081014
- Testing
- G-Pen Mini™ (glucagon injection)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Xeris Pharmaceuticals
Healthy, Type 1 Diabetes Mellitus
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
Study Design: Part 1.Randomized, double-blind, placebo-controlled, escalating single-dose design with Healthy volunteers Part 2.Open , sequential, two-period, single dose study with type 1 diabetes Part 3.Open, sequential…
- Conditions
- Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- HM12460A (NCT01724814)
- Testing
- HM12460A
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 1 Diabetes Mellitus
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c).
- Trial name
- IMAGINE 7 (NCT01792284)
- Testing
- LY2605541, Insulin Lispro
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
- Trial name
- QWINT-5 (NCT05463744)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 83 sites in United States, Argentina and 5 more
- Volunteers
- 692 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type1 diabetes on insulin injection therapy to investigate how the body processes a test formulation of insulin lispro and the effect of the test formulation on blood sugar levels.
- Trial name
- NCT02623452
- Testing
- Insulin Lispro
- Sponsor
- Eli Lilly and Company
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
- Trial name
- NCT03332849
- Testing
- HM12470
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Solid Tumor Cancer
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors.
- Trial name
- NCT06934616
- Testing
- GB268
- Volunteers
- 330 people
- Sponsor
- Genor Biopharma Co., Ltd.
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00593255
- Testing
- soluble human insulin, insulin aspart, insulin NPH
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
The addition of Biochaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to a facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02029924
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
Mylan Insulin Aspart Study
The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.
- Trial name
- NCT03760068
- Testing
- MYL-1601D Product, FlexPen NovoLog®
- Where
- 158 sites in United States
- Volunteers
- 478 people
- Sponsor
- Mylan Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitis
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
- Trial name
- NCT07242664
- Testing
- GZR-33
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria
- Trial name
- NCT01756703
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 43 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 67 people
- Sponsor
- Tanabe Pharma Corporation
Type 1 Diabetes Mellitus
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years.
- Trial name
- NCT02239354
- Testing
- VC-01™ Combination Product
- Where
- 2 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- ViaCyte
Diabetes (Insulin-requiring, Type 1 or Type 2)
MiniMed Fit Payload Wear Study
The purpose of this study is to assess success/failure of the MiniMed Fit Payload adhesive components in different wear locations over a 7-day period to support development of the future commercialized patch pump.
- Trial name
- NCT07408141
- Testing
- MiniMed Fit Payload adhesive components
- Where
- 4 sites in United States
- Volunteers
- 159 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
The main objective is to determine the feasibility of dasiglucagon in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- STABLE-1 (NCT05454709)
- Testing
- Dasiglucagon, GlucaGen
- Where
- Netherlands
- Sponsor
- Inreda Diabetic B.V.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.